Evidence map›Paper›PMID 39948336›Full record

ArticleNature communications2025

Comprehensive dissection of cis-regulatory elements in a 2.8 Mb topologically associated domain in six human cancers.

Christina M Caragine, Victoria T Le, Meer Mustafa, Bianca Jay Diaz, John A Morris, Simon Müller, Alejandro Mendez-Mancilla, Evan Geller, Noa Liscovitch-Brauer, Neville E Sanjana

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Christina M Caragine *New York Genome Center, New York, NY, USA.
Victoria T Le *New York Genome Center, New York, NY, USA.
Meer MustafaNew York Genome Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-2638-9523
Bianca Jay DiazNew York Genome Center, New York, NY, USA.
John A MorrisNew York Genome Center, New York, NY, USA.ORCID http://orcid.org/0000-0003-2769-8202
Simon MüllerNew York Genome Center, New York, NY, USA.
Alejandro Mendez-MancillaNew York Genome Center, New York, NY, USA.
Evan GellerNew York Genome Center, New York, NY, USA.
Noa Liscovitch-BrauerNew York Genome Center, New York, NY, USA.
Neville E SanjanaNew York Genome Center, New York, NY, USA. neville@sanjanalab.org.ORCID http://orcid.org/0000-0002-1504-0027

Funding

Predicting the functional impact of non-coding mutations using patient-specific gene regulatory networksR01CA218668 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI EKTA KHURANA, Neville Sanjana · 2018 to 2026
$4.7M
Multiscale genome engineering to map cis-regulatory variants in human and mouseR01HG012790 · NHGRI · NEW YORK GENOME CENTER · PI Tuuli Lappalainen, Dan Littman · 2023 to 2026
$4.5M
In situ functional genomics to understand transcriptional regulationDP2HG010099 · NHGRI · NEW YORK GENOME CENTER · PI SANJANA, NEVILLE · 2017 to 2022
$4.4M
Enhancing Susceptibility of HIV Reservoirs to CTL Through a Discovery to Translational ApproachR01AI176601 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI R. Brad Jones, Neville Sanjana · 2023 to 2026
$3.3M
LTBR CARs as next-generation therapies for R/R lymphomaR01CA279135 · NCI · NEW YORK GENOME CENTER · PI Catherine Sibyl Diefenbach, Neville Sanjana · 2023 to 2026
$3.2M
Scalable multi-ancestry functional genomics of blood traits and cardiovascular diseaseR01HL168247 · NHLBI · NEW YORK GENOME CENTER · PI Neville Sanjana · 2024 to 2026
$2.4M
NCI NIH HHS R01 CA218668NCI NIH HHS R01 CA279135NHGRI NIH HHS DP2 HG010099NHGRI NIH HHS R01 HG012790NHLBI NIH HHS R01 HL168247NIAID NIH HHS R01 AI176601U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (NHGRI) DP2HG10099
6 · The paper itself

Abstract

Cis-regulatory elements (CREs), such as enhancers and promoters, are fundamental regulators of gene expression and, across different cell types, the MYC locus utilizes a diverse regulatory architecture driven by multiple CREs. To better understand differences in CRE function, we perform pooled CRISPR inhibition (CRISPRi) screens to comprehensively probe the 2.8 Mb topologically-associated domain containing MYC in 6 human cancer cell lines with nucleotide resolution. We map 32 CREs where inhibition leads to changes in cell growth, including 8 that overlap previously identified enhancers. Targeting specific CREs decreases MYC expression by as much as 60%, and cell growth by as much as 50%. Using 3-D enhancer contact mapping, we find that these CREs almost always contact MYC but less than 10% of total MYC contacts impact growth when silenced, highlighting the utility of our approach to identify phenotypically-relevant CREs. We also detect an enrichment of lineage-specific transcription factors (TFs) at MYC CREs and, for some of these TFs, find a strong, tumor-specific correlation between TF and MYC expression not found in normal tissue. Taken together, these CREs represent systematically identified, functional regulatory regions and demonstrate how the same region of the human genome can give rise to complex, tissue-specific gene regulation.

Indexed as

Gene Expression Regulation, NeoplasticNeoplasmsProto-Oncogene Proteins c-mycRegulatory Sequences, Nucleic AcidCell Line, TumorCell ProliferationCRISPR-Cas SystemsEnhancer Elements, GeneticHumansPromoter Regions, GeneticTranscription FactorsMYC protein, humanProto-Oncogene Proteins c-mycTranscription Factors

Identifiers

PMID39948336
PMCPMC11825950

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.